MDxHealth Q4 2023 GAAP EPS $(0.390) Misses $(0.150) Estimate, Sales $19.398M Beat $18.136M Estimate
Portfolio Pulse from Benzinga Newsdesk
MDxHealth (NASDAQ:MDXH) reported Q4 2023 GAAP EPS of $(0.390), missing the $(0.150) estimate by 160%, but sales of $19.398M exceeded the $18.136M estimate by 6.96%, marking a 50.48% increase from the previous year.
March 06, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
MDxHealth reported a larger than expected Q4 2023 loss per share but exceeded sales estimates, showing significant year-over-year growth.
The mixed results with a significant miss on EPS but a beat on sales revenue and notable year-over-year growth suggest a neutral short-term impact on MDxHealth's stock price. The negative impact of the earnings miss may be somewhat offset by the positive sales performance and growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100